Oncology
Esperas Pharma Inc. is focused on clinical research in advanced cancer and metastatic cancer, with activity centered on solid tumour treatment settings.
- Advanced or metastatic cancer
- Solid tumour oncology
- Anti-cancer therapeutics
The sponsor’s current research interest includes high-grade serous ovarian cancer, particularly within patients whose disease characteristics guide selection of targeted and combination treatment approaches.
Gynecologic Cancer
Clinical activity also extends to ovarian cancer, with attention to disease biology in BRCA1/2 wildtype populations and treatment options for advanced gynecologic malignancies.
- High-grade serous ovarian cancer
- BRCA1/2 wildtype
- Gynecologic oncology
This area reflects interest in therapies intended for patients with persistent or disseminated disease requiring systemic intervention.
Combination Anticancer Therapy
Esperas Pharma Inc. is involved in research on combination therapy for cancer, including regimens pairing investigational agents with established chemotherapy backbones.
- Combination regimens
- Chemotherapy-based treatment
- Therapeutic tolerability
Its clinical focus includes evaluating treatment compatibility and patient suitability in advanced disease contexts.
Targeted Cancer Treatment
The sponsor’s trial portfolio indicates interest in targeted oncology, with emphasis on molecularly informed treatment strategies for patients with advanced malignancy.
- Molecularly guided therapy
- Targeted antineoplastic agents
- Tumour-specific treatment strategies
Research activity in this area aligns with the development of therapies for patients whose disease has progressed beyond localized stages.
